바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.77 No.6
Citation Share

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2014, v.77 no.6, pp.258-261






& (2014). Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 77(6), 258-261.
  • Downloaded
  • Viewed
PDF Download

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement, is a kind of driver mutation, accounts for 3%−5% of non-small celllung cancer (NSCLC). NSCLC patients harboring ALK fusion genes have distinct clinical features and good responseto ALK inhibitors. Metastasis from lung cancer to the ovary has rarely been known. We report a case of a 54-year-oldwoman with bilateral ovarian metastases from ALK rearranged NSCLC. She underwent bilateral salpingo-oophorectomyfor ovary masses, which were progressed after cytotoxic chemotherapy although primary lung mass was decreased. Histopathological examination of the ovary tumor showed characteristic adenocarcinoma patterns of the lung and ALKrearrangement.

keywords
Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovary

Reference

1.

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.

2.

2. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-80.

3.

3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010;363:1693-703.

4.

4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.

5.

5. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51.

6.

6. Hayashi H, Okamoto I, Tanizaki J, Tanaka K, Okuda T, Kato A, et al. Cystic brain metastasis in non-small-cell lung cancer With ALK rearrangement. J Clin Oncol 2014;32:e122-4..

7.

7. Alvarado-Cabrero I, Rodriguez-Gomez A, Castelan-Pedraza J, Valencia-Cedillo R. Metastatic ovarian tumors: a clinicopathologic study of 150 cases. Anal Quant Cytopathol Histpathol 2013;35:241-8.

8.

8. Jung YE, Lee JW, Kim BG, Bae DS. Ovarian metastasis from pulmonary adenocarcinoma. Obstet Gynecol Sci 2013;56:341-4.

9.

9. Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T, Kohno I. Clinical implications of metastases to the ovary. Gynecol Oncol 1995;59:124-8.

10.

10. Irving JA, Young RH. Lung carcinoma metastatic to the ovary:a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol 2005;29:997-1006.

11.

11. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11.

12.

12. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in neversmokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90-7.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy